1250 citations
,
August 2021 in “Scientific Reports” In this study, researchers estimated that 80% of patients infected with SARS-CoV-2 experienced at least one long-term symptom, with fatigue being the most common.
32 citations
,
July 2021 in “Journal of The American Academy of Dermatology” This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.
213 citations
,
December 2020 in “Annals of internal medicine” This study observed that 32% of COVID-19 patients experienced persistent symptoms, including fatigue, dyspnea, and loss of taste or smell, 30 to 45 days after their initial diagnosis.
51 citations
,
November 2020 in “Journal of the European Academy of Dermatology and Venereology” This article discusses SARS-CoV-2-induced telogen effluvium in a multicentric study and reports no new clinical results.
88 citations
,
October 2020 in “Open Forum Infectious Diseases” This study discusses hair loss as a potential late-onset symptom of COVID-19 recovery, with androgenic alopecia and telogen effluvium suggested as possible causes, but provides no new clinical results.
737 citations
,
August 2020 in “Journal of Infection” This study found that most patients hospitalized for COVID-19 experienced persistent symptoms over 100 days post-admission, with no significant difference in symptoms between those treated in regular wards and intensive care units.